BACKGROUND: Moderate-to-severe atopic dermatitis (AD) is increasingly recognized as a systemic disease, largely due to proteomic blood studies. There are growing efforts to develop AD biomarkers using minimal tissues. OBJECTIVE: To characterize the AD skin proteomic signature and its relationship with the blood proteome and genomic skin profile in the same individuals. METHODS: We evaluated lesional and nonlesional biopsy samples and blood from 20 individuals with moderate-to-severe AD and 28 healthy individuals using Olink Proteomics (Uppsala, Sweden), using 10 μg/10 μL for skin and blood and RNA sequencing of the skin. RESULTS: The AD skin proteome demonstrated significant upregulation in lesional and even in nonlesional skin compared with controls in inflammatory markers (matrix metalloproteinase 12; T-helper cell [Th]2/interleukin [IL]-1 receptor-like 1[IL1RL1]/IL-33R, IL-13, chemokine [C-C motif] ligand [CCL] 17; Th1/C-X-C motif chemokine 10; Th17/Th22/PI3, CCL20, S100A12), and in cardiovascular-associated proteins (E-selectin, matrix metalloproteinases, platelet growth factor, myeloperoxidase, fatty acid binding protein 4, and vascular endothelial growth factor A; false discovery rate, <0.05). Skin proteins demonstrated much higher and significant upregulations (vs controls) compared with blood, suggesting a skin source for the inflammatory/cardiovascular profile. Gene and protein expressions were correlated (r = 0.410, P < .001), with commonly upregulated inflammatory and cardiovascular risk-associated products, suggesting protein translation in skin. LIMITATIONS: Our analysis was limited to 354 proteins. CONCLUSIONS: The AD skin proteome shows an inflammatory and cardiovascular signature even in nonlesional skin, emphasizing the need for proactive treatment. Skin proteomics presents a sensitive option for biomarker monitoring.
BACKGROUND: Moderate-to-severe atopic dermatitis (AD) is increasingly recognized as a systemic disease, largely due to proteomic blood studies. There are growing efforts to develop AD biomarkers using minimal tissues. OBJECTIVE: To characterize the AD skin proteomic signature and its relationship with the blood proteome and genomic skin profile in the same individuals. METHODS: We evaluated lesional and nonlesional biopsy samples and blood from 20 individuals with moderate-to-severe AD and 28 healthy individuals using Olink Proteomics (Uppsala, Sweden), using 10 μg/10 μL for skin and blood and RNA sequencing of the skin. RESULTS: The AD skin proteome demonstrated significant upregulation in lesional and even in nonlesional skin compared with controls in inflammatory markers (matrix metalloproteinase 12; T-helper cell [Th]2/interleukin [IL]-1 receptor-like 1[IL1RL1]/IL-33R, IL-13, chemokine [C-C motif] ligand [CCL] 17; Th1/C-X-C motif chemokine 10; Th17/Th22/PI3, CCL20, S100A12), and in cardiovascular-associated proteins (E-selectin, matrix metalloproteinases, platelet growth factor, myeloperoxidase, fatty acid binding protein 4, and vascular endothelial growth factor A; false discovery rate, <0.05). Skin proteins demonstrated much higher and significant upregulations (vs controls) compared with blood, suggesting a skin source for the inflammatory/cardiovascular profile. Gene and protein expressions were correlated (r = 0.410, P < .001), with commonly upregulated inflammatory and cardiovascular risk-associated products, suggesting protein translation in skin. LIMITATIONS: Our analysis was limited to 354 proteins. CONCLUSIONS: The AD skin proteome shows an inflammatory and cardiovascular signature even in nonlesional skin, emphasizing the need for proactive treatment. Skin proteomics presents a sensitive option for biomarker monitoring.
Authors: Benjamin Ungar; Ana B Pavel; Philip M Robson; Audrey Kaufman; Alison Pruzan; Patrick Brunner; Shivani Kaushik; James G Krueger; Mark G Lebwohl; Venkatesh Mani; Zahi A Fayad; Emma Guttman-Yassky Journal: J Allergy Clin Immunol Pract Date: 2020-07-25
Authors: David J Margolis; Nandita Mitra; Brian S Kim; Jamie L Duke; Ron A Berna; Ole J Hoffstad; Jenna R Wasserman; Deborah A Ferriola; Tim L Mosbruger; Bradley S Wubbenhorst; Kathrine L Nathanson; Dimitri S Monos Journal: J Immunol Date: 2021-04-16 Impact factor: 5.422
Authors: Maxim A X Tollenaere; Thomas Litman; Lena Moebus; Elke Rodriguez; Dora Stölzl; Katharina Drerup; Thomas Werfel; Jochen Schmitt; Hanne Norsgaard; Stephan Weidinger Journal: Acta Derm Venereol Date: 2021-04-29 Impact factor: 3.875
Authors: Tesfaye B Mersha; Yashira Afanador; Elisabet Johansson; Steven P Proper; Jonathan A Bernstein; Marc E Rothenberg; Gurjit K Khurana Hershey Journal: Clin Rev Allergy Immunol Date: 2021-04 Impact factor: 8.667
Authors: Kristina Navrazhina; Sandra Garcet; John W Frew; Xiuzhong Zheng; Israel Coats; Emma Guttman-Yassky; James G Krueger Journal: J Am Acad Dermatol Date: 2021-07-30 Impact factor: 11.527
Authors: Helen He; Caroline M Olesen; Ana B Pavel; Maja-Lisa Clausen; Jianni Wu; Yeriel Estrada; Ning Zhang; Tove Agner; Emma Guttman-Yassky Journal: Front Immunol Date: 2020-08-06 Impact factor: 7.561